Vista Pharmaceuticals Ltd (524711)
🎯 Key Takeaways
- Vista Pharmaceuticals Ltd appears to be in a distressed phase, marked by persistent losses, negative returns, and minimal revenue generation. The company has not generated meaningful revenue in recent quarters, with only sporadic and nominal sales reported, primarily in late 2025.
- ⚠️ Persistent negative profitability across all metrics with no signs of operational improvement.
📖 The Story
Vista Pharmaceuticals Ltd appears to be in a distressed phase, marked by persistent losses, negative returns, and minimal revenue generation. The company has not generated meaningful revenue in recent quarters, with only sporadic and nominal sales reported, primarily in late 2025. Its financials reflect a business struggling to maintain operations, with negative operating and net profits across all recent periods. The absence of revenue growth and ongoing losses suggest a potential liquidity or survival challenge rather than a growth or turnaround narrative.
📰 What's Happening
Management has not announced any new product launches, regulatory approvals, or strategic partnerships in recent filings. There are no indications of major capital raises, acquisitions, or divestitures. The company continues to operate with minimal revenue, reporting ₹2 crore in revenue as late as September 2025, followed by zero revenue in December 2025 and June 2026. No new orders or contract wins have been disclosed in the latest filings, and there is no evidence of a turnaround strategy being actively pursued. The business appears to be in a state of suspended operations, with no visible catalysts announced by management.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 2 | 1 | 2 | 0 | 0 |
| Operating Profit | -1 | -4 | -3 | -7 | -1 |
| OPM % | -84.2% | -249.3% | -131.8% | — | — |
| Net Profit | -1 | -3 | -2 | -6 | -1 |
| EPS | ₹-0.24 | ₹-0.42 | ₹-0.41 | ₹-0.91 | ₹-0.16 |
Revenue has declined sharply from ₹2 crore in September 2025 to ₹1 crore in December 2025 and then to zero in March 2026 and June 2026, indicating a complete erosion of sales. Operating losses have worsened, with operating expenses exceeding revenue by significant margins — for instance, an OPM of -249.3% in September 2025. Net losses have remained elevated, with EPS consistently negative, reflecting ongoing financial stress. The lack of revenue recovery despite no structural changes suggests the core business may be non-viable or in terminal decline.
🔮 Management Outlook & What's Next
There is no forward guidance or explicit outlook provided by management in the latest filings regarding revenue recovery, cost restructuring, or business revival. Management commentary is absent in the recent quarterly results, with no discussion of strategic alternatives, timelines for profitability, or expectations for operational resumption. The filings focus solely on reporting losses without offering any narrative on future prospects or corrective actions. This lack of transparency around future performance raises concerns about visibility into the company’s trajectory.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 |
| Reserves | 36 | 33 | 32 | 24 |
| Borrowings | 7 | 7 | 9 | 10 |
| Total Liabilities | 64 | 60 | 61 | 55 |
| Fixed Assets | 9 | 19 | 9 | 9 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 64 | 60 | 61 | 55 |
The balance sheet shows a stable equity base of ₹12 crore over recent periods, with reserves declining slightly from ₹33 crore to ₹24 crore, suggesting limited retained earnings due to losses. Borrowings remain low at ₹9–10 crore, indicating minimal debt pressure, but total assets have plateaued around ₹55–61 crore without signs of growth or investment. There is no evidence of aggressive capital allocation — no new investments or asset acquisitions are disclosed. The capital structure remains conservative, but the lack of reinvestment or operational scaling suggests management is not pursuing expansion or recovery.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -7 |
| Investing | -0 |
| Financing | +8 |
| Net Cash Flow | +1 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 21.2% | 21.2% | 21.2% | 21.2% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 33.6% | 33.6% | 33.6% | 33.6% |
| # Shareholders | 14,012 | 14,080 | 14,154 | 14,154 |
Promoter holding remains unchanged at 21.19% across all recent quarters, with no signs of accumulation or reduction. Institutional ownership is nearly negligible, with FII holding at 0% and DII at just 0.02%, suggesting no investor confidence or interest. The shareholder base is highly dispersed, with over 14,000 public shareholders, which may reflect retail-held stock with low liquidity. There are no indications of activist activity or significant stakebuilding by any party. The lack of institutional interest reinforces the perception of a neglected or uninvestable company.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.42 L Cr | 36.5 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.48 L Cr | 84.6 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.89 L Cr | 79.4 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.12 L Cr | 24.9 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.10 L Cr | 32.7 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.06 L Cr | 97.3 | 20.8% | 20.6% | 0.45 |
| DRREDDY | 96,906 | 30.0 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 96,402 | 26.2 | 12.8% | 9.8% | 0.20 |
| LUPIN | 95,836 | 16.9 | 27.9% | 24.7% | 0.26 |
| MANKIND | 94,039 | 46.0 | 13.9% | 12.7% | 0.38 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent negative profitability across all metrics with no signs of operational improvement. 2. Complete absence of revenue in the two most recent quarters, raising concerns about business continuity. 3. No disclosed strategy or management commentary to address the crisis, indicating potential governance or strategic inertia. 4. High operational cost structure relative to minimal revenue, leading to unsustainable cash burn. These factors combine to create a high-risk profile with limited upside potential unless a clear turnaround path emerges.
🧠 Analyst's Read
Vista Pharmaceuticals is currently in a critical survival phase with no visible catalysts for recovery. The company’s financials reflect a business in decline, and without management articulation of a turnaround plan or signs of revenue revival, the risk of delisting or delisting remains elevated. Investors should monitor for any future announcements regarding restructuring, partnerships, or asset divestment as potential inflection points. Until then, the company lacks the fundamental indicators of a viable pharmaceutical business.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-13.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd